预约演示
更新于：2025-08-31
Telmisartan
替米沙坦
更新于：2025-08-31
概要
基本信息
药物类型 小分子化药 |
别名 4'-[(1,4'-dimethyl-2'propyl[2,6'-bi-1H-benzimidazol]-1'-yl)methyl]-[1,1'-biphenyl]-2-carboxylic acid、4'-[(1,7'-dimethyl-2'-propyl-1H,3'H-2,5'-bibenzimidazol-3'-yl)methyl]biphenyl-2-carboxylic acid、Telmisartan + [68] |
靶点 |
作用方式 拮抗剂 |
作用机制 AT1R拮抗剂(血管紧张素II-1型受体拮抗剂) |
治疗领域 |
非在研机构- |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1998-11-10), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C33H30N4O2 |
InChIKeyRMMXLENWKUUMAY-UHFFFAOYSA-N |
CAS号144701-48-4 |
关联
336
项与 替米沙坦 相关的临床试验NCT06815497
Phase II Non-Randomized, Unblinded, Single-Center Trial of Telmisartan in Combination With Cytotoxic Regimens in Platinum-Resistant Ovarian Cancer Versus Historical Best Supportive Care
NCT06647745
A Randomized, Double-blind, Multi-center, Active-controlled, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy of THP-00101, THP-00102, and THP-00103 in Subjects With T2DM and Essential Hypertension
TCTR20241006001
A Randomized, Double-blind, Multi-center, Active-controlled, Phase 3 clinical trial to Evaluate the Efficacy and Safety of Combination Therapy of THP-00101, THP-00102, and THP-00103 in Subjects with T2DM and Essential Hypertension
100 项与 替米沙坦 相关的临床结果
登录后查看更多信息
100 项与 替米沙坦 相关的转化医学
登录后查看更多信息
100 项与 替米沙坦 相关的专利（医药）
登录后查看更多信息
4,303
项与 替米沙坦 相关的文献（医药）2025-12-01JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY A-CHEMISTRY
Aquatic photochemistry and transformations of multiclass emerging organic contaminants in environmental water matrices
作者: Bajt, Oliver ; Prosen, Helena ; Kravos, Aleksander
This study shows a comprehensive assessment of the photodegradation of 18 multiclass contaminants of emerging concern (CECs) in simulated river and marine aquatic compartments.Degradation trends, mineralization, and defluorination of the target CECs were monitored in model matrixes, artificial and real seawater, with and without aeration.Each model matrix contained a natural abiotic factor of interest, i.e., chloride, nitrate, humic acid, lignosulfonate, and iron, all naturally present in surface water.Transformation pathways were investigated by UHPLC-MS/MS and for the identified transformation products (TPs), their ecotoxicities were predicted in silico.Only 8 out of 18 selected CECs were found to be significantly photolabile, especially rosuvastatin.Direct photolysis was their primary degradation route, while abiotic factors either accelerated or suppressed the degradation depending on the type of CEC.Real and artificial seawater mostly acted inhibitory.Oxygen aeration mostly accelerated degradation showing the effect of singlet oxygen.Low mineralization and defluorination were in most cases linked to the formation of stable and relatively more toxic TPs, which were characteristic for rosuvastatin.Main identified TPs were screened in real river water and seawater (North Adriatic Sea water basin, Slovenia, Europe).Rosuvastatin′s TP ROS-349 was detected with a high confidence level for the first time, which may raise environmental concerns.Overall, advanced assessment of aquatic photochem. is achieved by using low concentrations, mixtures of multiclass CECs, UV light above 300 nm, more realistic matrixes, as well as by identifying, ranking, and analyzing the TPs in actual aquatic environment.
2025-11-01Current Vascular Pharmacology
Efficacy of Dapagliflozin and Telmisartan Combination Therapy in
Reducing Albuminuria and Inflammatory Markers in Diabetic
Nephropathy: A Prospective Observational Study
Article
作者: Bhandari, Uma ; Chauhan, Shalu ; Habib, Anwar
Background::
Diabetic nephropathy, a major contributor to chronic kidney disease, is
closely associated with inflammatory responses.
Objective::
This study aimed to evaluate the effectiveness of combination therapy with dapagliflozin
and telmisartan in treating diabetic nephropathy and its effect on patient’s albuminuria levels.
Material and Methods::
We conducted a 12-week prospective observational study to assess diabetic
nephropathy. Patients with diabetic nephropathy were treated with either dapagliflozin and telmisartan
(n=92) or telmisartan alone (n=92). Measurements of waist-to-hip ratio, fasting blood glucose,
hemoglobin A1c (HbA1c), blood pressure, urinary albumin-to-creatinine ratio (UACR), estimated
glomerular filtration rate (eGFR), uric acid, blood urea nitrogen, lipid profile, and inflammatory biomarkers,
including C-C motif chemokine ligand 21 messenger RNA (CCL21 mRNA) and monocyte
chemoattractant protein-1 (MCP-1), were obtained at baseline and following 12-weeks of treatment.
Results::
Dapagliflozin and telmisartan combination therapy demonstrated a significant decrease in
UACR compared with baseline levels (p<0.001). After treatment, the dapagliflozin and telmisartan
group had significantly lower waist-to-hip ratio, fasting blood glucose, HbA1c, uric acid, total cholesterol,
and low-density lipoprotein compared with the monotherapy group (p<0.05). Additionally,
inflammatory biomarkers, including CCL21 mRNA and MCP-1, were substantially lower in the
combination therapy group than in the monotherapy group (p<0.05).
Conclusion::
In comparison to monotherapy, combination therapy demonstrated more significant
clinical effects in treating diabetic nephropathy. This combination therapy effectively controls blood
glucose levels and UACR, reduces inflammatory responses, and improves kidney function recovery
in diabetic nephropathy patients, thereby enhancing the overall clinical treatment outcomes for these
patients.
2025-09-02INTERNATIONAL JOURNAL OF ENVIRONMENTAL ANALYTICAL CHEMISTRY
Development and application of a sustainable approach for the determination of 95 pharmaceutical substances and metabolites in urban wastewater by means of ultra-high-performance liquid-chromatography-tandem mass spectrometry
作者: Vincenti, Marco ; Gerace, Enrico ; Minella, Marco ; Privitera, Dana ; Salomone, Alberto ; Massano, Marta ; Alladio, Eugenio
In the last few years, the interest in pharmaceutical drugs and their metabolites as environmental pollutants is gaining growing importance.Regular monitoring and timely actions are decisive to implement appropriate water resource management strategies and to evaluate the efficiency of traditional or innovative wastewater treatment plants (WWTPs).This study describes the development and validation of an anal. procedure using 10 mL sample volume followed by direct-injection in ultra-high-performance liquid chromatog.-tandem mass spectrometry (UHPLC-MS/MS) for the simultaneous determination of 95 pharmaceutical drugs and 10 of their main metabolites in wastewater.Adequate sensitivity was recorded for all target analytes, with limits of detection below 5 ng/L for 60 out of 95 analytes and recoveries exceeding 80% for all the analytes under study.A total of 42 target analytes were detected in almost all sites, and limited differences were observed among several pharmaceutical drug arrays found at different sampling sites.In addition, an abatement yield higher than 50% was observed for only 12 of the 42 detected substances.The procedure, which combined direct injection and small sample volume collection, showed great potential and efficiency for the high-performance determination of pharmaceutical drugs in wastewater.
100 项与 替米沙坦 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 心血管疾病 | 欧盟 | 2010-09-29 | |
| 心血管疾病 | 冰岛 | 2010-09-29 | |
| 心血管疾病 | 列支敦士登 | 2010-09-29 | |
| 心血管疾病 | 挪威 | 2010-09-29 | |
| 原发性高血压 | 欧盟 | 1998-12-11 | |
| 原发性高血压 | 冰岛 | 1998-12-11 | |
| 原发性高血压 | 列支敦士登 | 1998-12-11 | |
| 原发性高血压 | 挪威 | 1998-12-11 | |
| 高血压 | 美国 | 1998-11-10 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 高甘油三酯血症 | 临床3期 | 德国 | 2007-11-01 | |
| 代谢综合征 | 临床3期 | 德国 | 2007-11-01 | |
| 高胆固醇血症 | 临床3期 | 美国 | 2006-04-01 | |
| 高胆固醇血症 | 临床3期 | 捷克 | 2006-04-01 | |
| 高胆固醇血症 | 临床3期 | 法国 | 2006-04-01 | |
| 高胆固醇血症 | 临床3期 | 德国 | 2006-04-01 | |
| 高胆固醇血症 | 临床3期 | 中国香港 | 2006-04-01 | |
| 高胆固醇血症 | 临床3期 | 荷兰 | 2006-04-01 | |
| 高胆固醇血症 | 临床3期 | 俄罗斯 | 2006-04-01 | |
| 高胆固醇血症 | 临床3期 | 斯洛伐克 | 2006-04-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 166 | (Diuretic) | 鬱獵繭願鏇築壓簾選築(醖範鑰簾淵窪壓顧糧鹽) = 齋鹹製鏇夢齋願鹹艱憲 齋獵願製鹽鏇築淵積製 (鹽醖襯窪壓遞鏇繭齋淵, 8.4) 更多 | - | 2025-07-29 | ||
(Calcium-channel Blocker) | 鬱獵繭願鏇築壓簾選築(醖範鑰簾淵窪壓顧糧鹽) = 觸膚膚夢窪窪範艱鏇齋 齋獵願製鹽鏇築淵積製 (鹽醖襯窪壓遞鏇繭齋淵, 9.2) 更多 | ||||||
临床3期 | 1,385 | GMRx2 (telmisartan 20 mg, amlodipine 2·5 mg, and indapamide 1·25 mg) | 蓋壓窪鏇製製膚構鏇簾(鏇齋願獵窪網糧膚網鑰) = 憲簾積網憲築襯淵糧製 鹹鹽廠鏇鑰淵簾鏇網窪 (糧積糧簾夢鏇範醖網鑰 ) | 积极 | 2024-10-01 | ||
临床1/2期 | 61 | (Telmisartan 20mg) | 醖蓋獵鹹憲蓋壓網網簾(鹽襯製製願夢鏇壓壓製) = 範襯鏇艱獵製鑰憲夢築 艱齋蓋範衊製範積鹹鹹 (獵願衊顧壓願網壓築簾, 1425.34) 更多 | - | 2024-05-23 | ||
(Telmisartan 40mg) | 醖蓋獵鹹憲蓋壓網網簾(鹽襯製製願夢鏇壓壓製) = 醖膚艱窪糧獵築衊衊膚 艱齋蓋範衊製範積鹹鹹 (獵願衊顧壓願網壓築簾, 1509.02) 更多 | ||||||
N/A | 32 | 鑰鹹襯衊鹹網鹹範鹽築 = 廠觸選願範範簾糧願鏇 遞網願襯憲選範糧網淵 (壓鏇齋憲夢襯廠膚範鏇, 鏇選網齋衊顧窪獵膚選 ~ 鏇餘簾衊鏇鬱餘鹹範網) 更多 | - | 2024-05-01 | |||
临床2期 | 24 | (Telmisartan) | 夢憲廠範網夢構簾顧蓋(夢鹽遞選網夢襯襯艱觸) = 壓膚醖餘艱網淵蓋構鹽 構觸鑰膚範憲願夢顧鏇 (範憲鏇餘範鬱繭壓鏇積, 鹽遞醖衊製網鏇顧簾鑰 ~ 鹹製簾遞鹽觸襯膚衊簾) 更多 | - | 2023-08-21 | ||
Placebo (Placebo) | 夢憲廠範網夢構簾顧蓋(夢鹽遞選網夢襯襯艱觸) = 構餘簾積繭獵餘膚糧蓋 構觸鑰膚範憲願夢顧鏇 (範憲鏇餘範鬱繭壓鏇積, 鏇齋製積選網憲繭夢製 ~ 淵齋醖積衊顧膚積蓋範) 更多 | ||||||
N/A | 107 | 鹽網繭構襯廠壓鑰簾積(醖觸顧鹽鬱顧鹽願壓膚) = 築衊鬱廠窪觸襯範憲鹽 顧鬱蓋構鹹積餘築選選 (餘築廠餘醖廠鬱築淵餘 ) 更多 | 积极 | 2023-08-08 | |||
Enalapril | 鹽網繭構襯廠壓鑰簾積(醖觸顧鹽鬱顧鹽願壓膚) = 衊範願鑰醖蓋醖襯觸膚 顧鬱蓋構鹹積餘築選選 (餘築廠餘醖廠鬱築淵餘 ) 更多 | ||||||
N/A | 107 | 糧餘網廠構夢網艱餘顧(蓋膚廠蓋蓋繭艱鹹鑰膚) = 構艱鬱範獵鬱鹽網衊製 簾醖積網顧蓋簾範簾餘 (憲蓋齋壓獵網簾繭膚夢 ) 更多 | - | 2023-05-20 | |||
Enalapril | 糧餘網廠構夢網艱餘顧(蓋膚廠蓋蓋繭艱鹹鑰膚) = 膚築構鑰鏇觸憲齋鑰築 簾醖積網顧蓋簾範簾餘 (憲蓋齋壓獵網簾繭膚夢 ) 更多 | ||||||
N/A | 114 | Supervised Treadmill Exercise Therapy+Telmisartan (Telmisartan + Supervised Treadmill Exercise Therapy) | 襯範鑰淵襯襯鏇廠構夢(醖鹽蓋艱襯餘衊醖築鏇) = 遞顧構鹽醖蓋積獵醖鬱 蓋襯鬱糧鬱顧衊積窪積 (壓糧壓蓋鬱鹹簾網艱廠, 67.21) 更多 | - | 2023-01-11 | ||
"No exercise" control group+Telmisartan (Telmisartan + "No Exercise" Control Group) | 襯範鑰淵襯襯鏇廠構夢(醖鹽蓋艱襯餘衊醖築鏇) = 鬱襯鹹選觸鬱繭壓醖鏇 蓋襯鬱糧鬱顧衊積窪積 (壓糧壓蓋鬱鹹簾網艱廠, 47.33) 更多 | ||||||
N/A | 114 | Telmisartan plus exercise | 顧範願範糧鬱衊構憲願(鑰範積鑰鏇醖鏇齋夢艱) = 餘鹽觸襯鬱窪顧窪膚網 壓鬱憲繭蓋製積鹹選鏇 (襯衊鬱製選觸鏇鏇觸衊 ) | 不佳 | 2022-10-04 | ||
Placebo plus exercise | 顧範願範糧鬱衊構憲願(鑰範積鑰鏇醖鏇齋夢艱) = 製餘蓋鏇憲網壓夢鑰遞 壓鬱憲繭蓋製積鹹選鏇 (襯衊鬱製選觸鏇鏇觸衊 ) | ||||||
临床2期 | 6 | 艱衊鹽鬱觸構糧構齋餘(衊憲艱鬱艱繭鑰艱憲構) = 壓夢鏇獵選積遞餘簾繭 構齋糧鹹鏇糧築鏇遞壓 (製餘襯淵鑰衊鹹醖網壓, 0.2377) 更多 | - | 2022-03-02 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用